



June 25, 2025

U. S. Nuclear Regulatory Commission
Region III
Materials Licensing Section
2443 Warrenville Road, Suite 210
Lisle, Illinois 60532

License Number 24-01090-03

To whom it may concern:

This letter is submitted for compliance with 10 CFR 35.14 Notifications:

1. We have allowed Duane Myers, M.D. to work as an authorized user under our license. We have approved his use of materials for 35.300. Attached is NRC license # 24-01090-03 Amendment No. 61, which specifically lists Dr. Myers for these materials. Please add him to our list of authorized users for these materials.
2. We have allowed Kimberly Creach, M.D. to work as an authorized user under our license. We have approved her use of materials for 35.300. Attached is NRC license # 24-00866-02, which specifically lists Dr. Creach for these materials. Please add her to our list of authorized users for these materials.
3. We have allowed Nathan Tonlaar, M.D. to work as an authorized user under our license. We have approved his use of materials for 35.300 (limited to the parenteral administration of unsealed byproduct material) for which a written directive is required. Attached is NRC license # 24-00866-02, which specifically lists Dr. Tonlaar for these materials. Please add him to our list of authorized users for these materials.
4. We have allowed Christopher Estes, M.D., to work as an authorized user under our license. We have approved his use of materials for 35.300 (limited to oral administration of sodium iodide I-131 and parenteral administration of any beta-emitter, or photon-emitting radionuclide with a photon energy less than 150 keV). Attached is NRC license # 24-00866-02, which specifically lists Dr. Estes for these materials. Please add him to our list of authorized users for these materials.
5. We have allowed Brandt Wible, M.D., to work as an authorized user under our license. We have approved his use of materials to include 35.100, 35.200, and 35.300 (limited to oral administration of sodium iodide I-131). Attached is NRC license # 24-00889-01, which specifically lists Dr. Wible for these materials. Please add him to our list of authorized users for these materials.



The Radiation Safety Committee has approved the above actions.

If you have any question regarding this notification, please contact me at (417) 556-4463 or email Samuel.Rhoades@Mercy.net

Sincerely,



Samuel Rhoades, Ph.D.
Radiation Safety Officer, Mercy Hospital Joplin

If you have any questions regarding this notification, please contact Samuel Rhoades, RSO, at (417) 556-4463 or email Samuel.Rhoades@Mercy.net

Sincerely,



Jeremy Drinkwitz
President, Mercy Hospital Joplin

To: Members of Radiation Safety Committee (RSC)

From: Samuel Rhoades, Ph.D., R.S.O.

Date: 06/24/2025

Subject: Duane Myers, M.D. has been granted Authorized User (AU) status for radioactive materials.

Please be advised that these Dr Myers has been approved by Administration and the RSC/RSO for the use of 35.300 materials.

This authorization is based on NRC license # 24-01090-03 Amendment No. 61, which specifically lists them for the above authorizations.


Administration will verify that they are licensed to practice medicine in the State of Missouri. This internal approval will be followed by submission within 30 days of their respective start dates as an Authorized User under Mercy-Joplin RAM license to the Nuclear Regulatory Commission.

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Mercy Hospital Joplin</p> <p>2. 100 Mercy Way Joplin, MO 64804</p>	<p>In accordance with letter dated March 29, 2021.</p>	<p>4. Expiration Date: December 31, 2023</p>
	<p>3. License No.: 24-01090-03 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-12728 Reference No.:</p>

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. Any imaging and localization study permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 400 millicuries total	C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.




**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-01090-03

Docket or Reference No.:
030-12728

Amendment No. 61

- | | | | |
|---|---|--|---|
| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license | 9. Authorized use |
| D. Iodine-125 permitted by 10 CFR 35.400 | D. Sealed Sources (Bard Brachytherapy, Inc., Model STM 1251; Best Medical International, Model 2300 Series; Core Oncology, Inc., Model I-125SL, I-125SH; International Brachytherapy, Inc., Model 1251L; IsoAid, Model IAI-125A; Medi-Physics, Model 6711, 6733; North American Scientific, Inc., Model MED 3631; Syncor, Model BT-125-I) | D. 800 millicuries total | D. Any manual brachytherapy procedure permitted by 10 CFR 35.400. |
| E. Palladium-103 permitted by 10 CFR 35.400 | E. Sealed Sources (Best Medical International, Model 2300 Series; International Brachytherapy, Inc., Model 1031L; North American Scientific, Inc., Model MED 3633; Theragenics Corp., Model 200) | E. 800 millicuries total | E. Any manual brachytherapy procedure permitted by 10 CFR 35.400. |
| F. Gold-198 permitted by 10 CFR 35.400 | F. Sealed Sources (Best Medical International, Model 81-02) | F. 500 millicuries total | F. Any manual brachytherapy procedure permitted by 10 CFR 35.400. |
| G. Cesium-131 permitted by 10 CFR 35.400 | G. Sealed Sources (IsoRay, Model CS-1 Lawrence CESERION Cs-131) | G. 5 curies total | G. Any manual brachytherapy procedure permitted by 10 CFR 35.400. |



**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-01090-03

Docket or Reference No.:
030-12728

Amendment No. 61

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at 100 Mercy Way, Joplin, Missouri, 64804.
11. The Radiation Safety Officer for this license is Samuel Rhoades, Ph.D.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized User (M.D., D.O., etc.)</u> | <u>Material and Use</u> |
|---|--|
| Lance H. Borup, D.O. | 10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries). |
| Thomas Kevin Ceballos, M.D. | 10 CFR 35.100 and 35.200. |
| Robert C. Frazier, M.D. | 10 CFR 35.300 |
| Duane Eugene Myers, M.D. | 10 CFR 35.300 and 35.400. |
| Theresa Pagliuca, M.D. | 10 CFR 35.300 |
| Richard J. Price, M.D. | 10 CFR 35.100 and 35.200. |
| Jacob Andrew Sedrick, D.O. | 10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide I-131). |
| Grzegorz Mariusz Szarnecki, M.D. | 10 CFR 35.100 and 35.200. |
| Steven J. Taggart, M.D. | 10 CFR 35.100, 35.200 and 35.300. |

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-01090-03

Docket or Reference No.:
030-12728

Amendment No. 61

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated October 1, 2013 (ML13281A935)
 - B. Letter received April 22, 2014 (ML14112A205)
 - C. Letter dated December 3, 2014 (ML14339A761)
 - D. Letter dated March 23, 2015 (ML15090A609)
 - E. Letter dated April 30, 2015 (ML15127A342)
 - F. Letter dated February 12, 2016 (ML16047A351)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Magdalena R.

By: GryglakMagdalena R. Gryglak
Region 3Digitally signed by Magdalena R.
Gryglak
Date: 2021.06.23 09:06:49 -05'00'Date: June 23, 2021

To: Members of Radiation Safety Committee (RSC)

From: Samuel Rhoades, Ph.D., R.S.O.

Date: 06/24/2025

Subject: Nathan Tonlaar, M.D., Kimberly Creach, M.D. and Christopher Estes, M.D. have been granted Authorized User (AU) status for radioactive materials.

Please be advised that these Dr Tonlaar has been approved by Administration and the RSC/RSO for the use of 35.300 (limited to parenteral administration of unsealed byproduct material) materials.

Please be advised that these Dr Creach has been approved by Administration and the RSC/RSO for the use of 35.300 materials.

Please be advised that these Dr Estes has been approved by Administration and the RSC/RSO for the use of 35.300 (limited to oral administration of sodium iodide I-131 and parenteral administration of any beta emitter, or a photon-emitting radionuclide with a photon energy less than 150 keV) materials.

This authorization is based on NRC license # 24-00866-02, which specifically lists them for the above authorizations.

Administration will verify that they are licensed to practice medicine in the State of Missouri. This internal approval will be followed by submission within 30 days of their respective start dates as an Authorized User under Mercy-Joplin RAM license to the Nuclear Regulatory Commission.

Official Use Only - Security-Related Information

NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 9 PAGES

Amendment No. 101

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee		In accordance with letter dated October 30, 2024,	4. Expiration Date: October 31, 2026
1. Mercy Hospital Springfield			5. Docket No.: 030-02285 Reference No.:
2. 1235 E. Cherokee St. Springfield, MO 65804		3. License No.: 24-00866-02 is amended in its entirety to read as follows:	
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie total	C. For any use permitted by 10 CFR 35.300.

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 2 OF 9 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-00866-02

Docket or Reference No.:
030-02285

Amendment No. 101

- | | | | |
|---|--|---|--|
| <p>6. Byproduct, source, and/or special nuclear material</p> <p>D. Iodine-125 permitted by 10 CFR 35.400</p> <p>E. Palladium-103 permitted by 10 CFR 35.400</p> | <p>7. Chemical and/or physical form</p> <p>D. Sealed Sources (Bard Brachytherapy, Inc, Model Intersource 1251L implant seeds and STM 1251; Best Medical International, Model 2300 Series; Core Oncology, Inc., Model I-125 SL and I-125 SH; International Brachytherapy, Inc., Model 1251L; IsoAid L.L.C., Model IAI-125A (Advantage I-125); Medi-Physics, Inc., Model 6711 (OncoSeed) and 6733 (EchoSeed); North American Scientific, Inc., Model MED 3631; Syncor Pharmaceuticals, Inc., Model BT-125-I)</p> <p>E. Sealed Sources (Best Medical International, Inc, Model 2300 Series (including 2335); International Brachytherapy, Inc., Model InterSource 1031L implant seeds; Mills Biopharmaceuticals, Inc., Model Model PD-103 SL and Pd-103SH; North American Scientific, Inc., Model MED 3633; Theragenics Corporation, Model TheraSeed 200)</p> | <p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>D. 1 curie total</p> <p>E. 1 curie total</p> | <p>9. Authorized use</p> <p>D. For any manual brachytherapy procedure permitted by 10 CFR 35.400.</p> <p>E. For any manual brachytherapy procedure permitted by 10 CFR 35.400.</p> |
|---|--|---|--|

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 3 OF 9 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-00866-02

Docket or Reference No.:
030-02285

Amendment No. 101

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
F. Any byproduct material permitted by 10 CFR 31.11	F. Prepackaged Kits	F. 10 millicuries total	F. For use in in-vitro studies.
G. Uranium- depleted in Uranium-235	G. Cadmium plated metal	G. 99 kilograms total	G. Shielding in a linear accelerator.
H. Cesium-137	H. Sealed Sources (Tech Ops, Model 77032)	H. 200 millicuries per source and 200 millicuries total	H. For use in Tech Ops. Model 773 gamma survey instrument calibrator for instrument calibration only.
I. Iridium-192 permitted by 10 CFR 35.600	I. Sealed Sources (Alpha Omega Services, Mallinckrodt Medical BV, NTP Radioisotopes (Europe) S.A., Model VS2000)	I. Two sources; 13 curies per source; 21 curies total	I. One source for medical use permitted by 10 CFR 35.600, in a Varian Medical Systems UK Ltd Model VariSource iX HDR remote afterloader; and for calibrations, spot checks and training. The source activity may not exceed 11 curies at the time of medical use. One source in its shipping container as necessary for replacement of the source in the remote afterloader unit.
J. Yttrium-90 permitted by 10 CFR 35.1000	J. Microspheres (Sirtex Medical Limited, Model SIR-Spheres microspheres)	J. 324 millicuries total	J. For medical use, as permitted by 10 CFR 35.1000, in a Sirtex Medical Limited brachytherapy afterloader delivery system.

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 4 OF 9 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-00866-02

Docket or Reference No.:
030-02285

Amendment No. 101

CONDITIONS

10. A. Licensed material, excluding Subitem No. 6.I., may be used or stored at the licensee's facilities located at 1235 E. Cherokee St., Springfield, MO 65804.
- B. Licensed material listed in Subitem Nos. 6.C. (limited to samarium-153) and 6.I. may be used or stored at the Mercy C.H. "Chub" O'Reilly Cancer Center, 2055 S. Fremont, Springfield, MO 65804.
- C. Licensed material listed in Subitem Nos. 6.A. and 6.B. may be used or stored at Mercy Hospital Lebanon, 100 Hospital Dr., Lebanon, MO 65536.
- D. Licensed material listed in Subitem No. 6.B., limited to technetium-99m, may be used or stored at the Ambulatory Surgery Center, 1229 E Seminole St., Springfield, MO 65804.
11. A. The Radiation Safety Officer (RSO) for this license is Jesse L. Whitlock, M.S.
- B. The Associate Radiation Safety Officer (ARSO) for this license is Scott Jones, Ph.D. for 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300, 10 CFR 35.400, 10 CFR 35.600 (limited to iridium-192 in a high dose rate remote afterloading brachytherapy unit), and 35.1000 (limited to Y-90 as SIR-Spheres).
- C. The Associate Radiation Safety Officer (ARSO) for this license is Neelu Soni, M.S. for 10 CFR 35.600 (limited to iridium-192 in a high dose rate remote afterloading brachytherapy unit).
- D. The Associate Radiation Safety Officer (ARSO) for this license is Richard Siska, for 10 CFR 35.100 and 10 CFR 35.200.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users, and/or authorized medical physicists in accordance with 10 CFR 35.13 and 10 CFR 35.14.

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 5 OF 9 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-00866-02

Docket or Reference No.:

030-02285

Amendment No. 101

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D.,D.O.,etc.)

Material and Use

Sharad Bansal, M.D.

10 CFR 35.200

Jordan A. Chance, M.D.

10 CFR 35.100,10 CFR 35.200

Kimberly M. Creach, M.D.

10 CFR 35.300,10 CFR 35.400,10 CFR 35.600 (limited to iridium-192 in a high dose rate remote afterloading brachytherapy unit)

Anthony R. DiVito, M.D.

10 CFR 35.100,10 CFR 35.200

Christopher F. Estes, M.D.

10 CFR 35.300 (limited to oral administration of sodium iodide I-131 and parenteral administration of any beta emitter, or a photon-emitting radionuclide with a photon energy less than 150 keV),10 CFR 35.400,10 CFR 35.600 (limited to iridium-192 in a high dose rate remote afterloading brachytherapy unit)

Ryan M. Hegg, M.D.

10 CFR 35.200,10 CFR 35.1000 (limited to yttrium-90 as SIR-Spheres)

Donald Myears, M.D.

10 CFR 35.200

Robert E. Sonnemaker, M.D.

10 CFR 31.11,10 CFR 35.100,10 CFR 35.200,10 CFR 35.300

Jacob S. Taussig, M.D.

10 CFR 35.200,10 CFR 35.1000 (limited to yttrium-90 as SIR-Spheres)

Johnson Thomas, M.D.

10 CFR 35.300, (limited to the oral administration of sodium iodide I-131)

Nathan Tonlaar, M.D.

10 CFR 35.300 (limited to the parenteral administration of unsealed byproduct material),10 CFR 35.400,10 CFR 35.600 (limited to iridium-192 in a high dose rate remote afterloading brachytherapy unit)

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 6 OF 9 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-00866-02

Docket or Reference No.:
030-02285

Amendment No. 101

C. The following individuals are authorized medical physicists for the materials and uses as indicated:

Authorized Medical Physicist

Veera Rajesh Gutti, Ph.D.

Julius Ojwang, Ph.D.

Neelu Soni, M.S.

Material and Use

Iridium-192 for use in a High Dose Rate Remote afterloading brachytherapy unit; and for calibrations, spot checks and training

Iridium-192 for use in a High Dose Rate Remote afterloading brachytherapy unit; and for calibrations, spot checks and training

Iridium-192 for use in a High Dose Rate Remote afterloading brachytherapy unit; and for calibrations, spot checks and training

D. Licensed material listed in Subitem No. 6.H. is authorized for use by, or under the supervision of, Jesse L. Whitlock, M.S., for instrument calibration.

13. Pursuant to Title 10, Chapter 1, Code of Federal Regulations, Part 40, "Domestic Licensing of Source Material," the licensee is authorized to possess, use, transfer, and import up to 999 kilograms of depleted uranium contained as shielding material in the molybdenum-99/technetium-99m generators authorized by this license.
14. Survey instrument calibrations shall be performed by Jesse L. Whitlock, M.S., or by other persons specifically licensed by the Commission or an Agreement State to perform such services.
15. Tests for leakage and/or contamination shall be performed by Jesse L. Whitlock, M.S., or other persons specifically licensed by the Commission or an Agreement State to perform such services.
16. For sealed sources not associated with 10 CFR 35 use, the following conditions apply:

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 7 OF 9 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-00866-02

Docket or Reference No.:

030-02285

Amendment No. 101

- A. Sealed sources and detector cells shall be tested for leakage and/or contamination at intervals not to exceed the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or by an Agreement State. In the absence of a registration certificate, sealed sources shall be tested for leakage and/or contamination at intervals not to exceed 6 months, or at such other intervals as specified.
- B. In the absence of a certificate from a transferor indicating that a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or by an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.
- C. Sealed sources need not be tested if they contain only hydrogen-3; or they contain only a radioactive gas; or the half-life of the isotope is 30 days or less; or they contain not more than 100 microcuries of beta- and/or gamma-emitting material or not more than 10 microcuries of alpha-emitting material.
- D. Sealed sources need not be tested if they are in storage and are not being used. However, when they are removed from storage for use or transferred to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.
- E. The leak test shall be capable of detecting the presence of 185 becquerels (0.005 microcuries) of radioactive material on the test sample. If the test reveals the presence of 185 becquerels (0.005 microcuries) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.
- F. Tests for leakage and/or contamination, including leak test sample collection and analysis, shall be performed by the licensee or other persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.
- G. Records of leak test results shall be kept in units of becquerels (microcuries) and shall be maintained for 3 years.

Official Use Only - Security-Related Information

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 8 OF 9 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-00866-02

Docket or Reference No.:
030-02285

Amendment No. 101

17. The licensee shall conduct a physical inventory every 6 months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sealed sources and/or devices received and possessed under the license. Records of inventories shall be maintained for 3 years from the date of each inventory, and shall include the radionuclides, quantities, manufacturer's name and model numbers, and the date of the inventory.
18. Sealed sources containing licensed material shall not be opened or sources removed from source holders by the licensee, except as specifically authorized.
19. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated April 22, 2011 (ML111180208)
 - B. Letter dated June 3, 2011 (ML111580608)
 - C. Letter dated February 8, 2012, limited to name change information only (ML120400151)
 - D. Letter dated April 9, 2012 (ML12101A422)
 - E. Letter dated May 4, 2012 (ML12128A448)
 - F. Letter dated June 12, 2012 (ML12165A250)
 - G. Letter dated December 19, 2012 (ML12362A274)
 - H. Letter dated January 24, 2013 (ML13025A367)
 - I. Letter dated January 9, 2015 (ML15012A591)
 - J. Letter dated March 31, 2015 (ML15104A387)
 - K. Letter dated July 16, 2015 (ML15202A563)

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 9 OF 9 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License No.: 24-00866-02

Docket or Reference No.:
030-02285

Amendment No. 101

- L. Letter dated July 9, 2018 (ML18192A884)
- M. Letter dated August 22, 2018 (ML18235A085)
- N. Letter dated November 30, 2018 (ML18337A359)
- O. Letter dated January 15, 2020 (ML20024G095)
- P. Letter dated February 5, 2020 (ML20043E246)
- Q. Letter dated March 13, 2020 (ML20073M905)
- R. Letter dated March 16, 2020 (ML20079E132)
- S. Letter dated March 23, 2020 (ML20085G937)
- T. Letter dated September 23, 2021 (ML21267A511)
- U. Letter dated April 27, 2023 (ML23121A045)
- V. Letter dated July 14, 2023 (ML23198A099)
- W. Letter dated October 30, 2024 (ML24309A125)
- X. Letter dated December 26, 2024 (ML24365A058)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: December 31, 2024

By: **Laura B. Cender** Digitally signed by Laura B. Cender
 Date: 2024.12.31 09:48:42 -06'00'

Laura B. Cender
 Region 3

To: Members of Radiation Safety Committee (RSC)

From: Samuel Rhoades, Ph.D., R.S.O.

Date: 06/24/2025

Subject: Brandt Wible, M.D. has been granted Authorized User (AU) status for radioactive materials.

Please be advised that these Dr Wible has been approved by Administration and the RSC/RSO for the use of include 35.100, 35.200, and 35.300 (limited to oral administration of sodium iodide I-131) materials.

This authorization is based on NRC license # 24-00889-01, which specifically lists them for the above authorizations.

Administration will verify that they are licensed to practice medicine in the State of Missouri. This internal approval will be followed by submission within 30 days of their respective start dates as an Authorized User under Mercy-Joplin RAM license to the Nuclear Regulatory Commission.

Official Use Only - Security-Related Information

NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 7 PAGES
Amendment No. 96

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p align="center">Licensee</p> <p>1. Saint Luke's Health System</p> <p>2. 4401 Wornall Rd. Kansas City, MO 64111</p>	<p>In accordance with letter dated April 13, 2023,</p>	<p>4. Expiration Date: October 31, 2038</p>
	<p>3. License No.: 24-00889-01 is renewed in its entirety to read as follows:</p>	<p>5. Docket No.: 030-02286 Reference No.:</p>

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 3 curies total	C. For any use permitted by 10 CFR 35.300.
D. Iodine-125 permitted by 10 CFR 35.400	D. Sealed Sources (IsoAid, LLC, Model IAI-125A (Advantage I-125); Medi-Physics, Inc., Model 6711 (OncoSeed))	D. 2 curies total	D. For any manual brachytherapy procedure permitted by 10 CFR 35.400.

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 2 OF 7 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-00889-01

Docket or Reference No.:

030-02286

Amendment No. 96

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
E. Any byproduct material permitted by 10 CFR 35.500	E. Sealed Sources (Eckert & Ziegler Isotope Products, Inc., Model NES-8426 and NES-8497)	E. 2 curies total	E. For diagnostic medical use of sealed sources permitted by 10 CFR 35.500 in compatible devices registered in accordance with 10 CFR 30.32(g).
F. Yttrium-90 permitted by 10 CFR 35.1000	F. Microspheres (Nordion (Canada), Inc., Model TheraSphere; Sirtex Medical Limited, Model SIR-Spheres)	F. 2 curies total	F. For medical use in permanent manual brachytherapy using a compatible Nordion (Canada), Inc. Model TheraSphere or Sirtex Medical Limited Model SIR-Spheres dose delivery system as permitted by 10 CFR 35.1000.
G. Any byproduct material with Atomic Numbers 1 through 83	G. Any	G. Not to exceed 1 curie per radionuclide; 3 curies total	G. For medical use in medical diagnosis, therapy, and research in humans as defined in 10 CFR 30.4 and 10 CFR 35.2, excluding animal studies.
H. Iridium-192 permitted by 10 CFR 35.600	H. Sealed Sources (Alpha-Omega Services, Inc., Model BRAVOS 232A; Curium Netherlands B.V., Model BRAVOS 232A)	H. Two sources; 21.6 curies total	H. One source for medical use permitted by 10 CFR 35.600, in a Varian Medical Systems Hann, GMBH Model BRAVOS HDR remote afterloader. The source activity may not exceed 15 curies at the time of medical use. One source in its shipping container as necessary for replacement of the source in the remote afterloader unit.
I. Cesium-131 permitted by 10 CFR 35.400	I. Sealed Sources (IsoRay Medical, Model CS-1; Lawrence CSERION Cs-131 Brachytherapy Seed)	I. 15 millicuries per source and 3 curies total	I. For use in GT Medical Technologies Model GT-001 GammaTile sealed brachytherapy sources for any manual brachytherapy procedure permitted by 10 CFR 35.400.

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 3 OF 7 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-00889-01

Docket or Reference No.:
030-02286

Amendment No. 96

CONDITIONS

10. A. Licensed material shall be used or stored at the licensee's facilities located at Saint Luke's Hospital of Kansas City, 4401 Wornall Rd., Kansas City, Missouri, 64111.
- B. Licensed material listed in Subitem Nos. 6.A. through 6.C. and in Subitem No. 6.E. may also be used at the licensee's facilities located at Saint Luke's North Hospital, 5830 NW Barry Rd., Kansas City, Missouri, 64154.
- C. Licensed material listed in Subitem Nos. 6.A. through 6.C. and in Subitem No. 6.E. may also be used at the licensee's facilities located at Saint Luke's East Hospital, 100 NE Saint Luke's Blvd., Lee's Summit, Missouri, 64086.
- D. Licensed material listed in Subitem Nos. 6.A. through 6.C. and in Subitem No. 6.E. may also be used at the licensee's facilities located at Medical Office Building, 20 NE Saint Luke's Blvd., Lee's Summit, Missouri, 64086.
- E. Licensed material listed in Subitem Nos. 6.A. through 6.C. and in Subitem No. 6.E. may also be used at the licensee's facilities located at Saint Luke's Hospital of Chillicothe d/b/a Hedrick Medical Center, 2799 N Washington St., Chillicothe, Missouri, 64601.
11. The Radiation Safety Officer (RSO) for this license is Roy N. Sions.
12. A. The use of licensed material in or on humans shall be by an authorized user as defined in 10 CFR 35.2.
- B. Individuals designated to work as authorized users, authorized nuclear pharmacists, or authorized medical physicists, as defined in 10 CFR 35.2, shall meet the training, experience and recency of training criteria established in 10 CFR Part 35, and shall be designated in writing by the licensee's Radiation Safety Committee.
- C. Individuals designated to work as authorized users for the 10 CFR 35.1000 use of yttrium-90 as TheraSphere and/or SIR-Spheres shall meet the training requirements in letter dated October 13, 2023 (ML23286A259), and shall be designated in writing by the licensee's Radiation Safety Committee.
- D. Licensed material for other than human use shall be used by, or under the supervision of, individuals designated in writing by the Radiation Safety Committee.

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 4 OF 7 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-00889-01

Docket or Reference No.:
030-02286

Amendment No. 96

13. For sealed sources not associated with 10 CFR Part 35 use, the following conditions apply:

- A. Sealed sources and detector cells shall be tested for leakage and/or contamination at intervals not to exceed the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or by an Agreement State. In the absence of a registration certificate, sealed sources shall be tested for leakage and/or contamination at intervals not to exceed 6 months, or at such other intervals as specified.
- B. Notwithstanding Paragraph A of this Condition, sealed sources designed to primarily emit alpha particles shall be tested for leakage and/or contamination at intervals not to exceed 3 months.
- C. In the absence of a certificate from a transferor indicating that a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or by an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.
- D. Sealed sources need not be tested if they contain only hydrogen-3; or they contain only a radioactive gas; or the half-life of the isotope is 30 days or less; or they contain not more than 100 microcuries of beta- and/or gamma-emitting material or not more than 10 microcuries of alpha-emitting material.
- E. Sealed sources need not be tested if they are in storage and are not being used. However, when they are removed from storage for use or transferred to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.
- F. The leak test shall be capable of detecting the presence of 185 becquerels (0.005 microcuries) of radioactive material on the test sample. If the test reveals the presence of 185 becquerels (0.005 microcuries) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.

Official Use Only - Security-Related Information

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 5 OF 7 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-00889-01

Docket or Reference No.:

030-02286

Amendment No. 96

- G. Tests for leakage and/or contamination, including leak test sample collection and analysis, shall be performed by the licensee or other persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.
- H. Records of leak test results shall be kept in units of becquerels (microcuries) and shall be maintained for 3 years.
14. For licensed material not associated with 10 CFR Part 35 use, the licensee shall conduct a physical inventory every 6 months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sealed sources and/or devices received and possessed under the license. Records of inventories shall be maintained for 3 years from the date of each inventory, and shall include the radionuclides, quantities, manufacturer's name and model numbers, and the date of the inventory.
15. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee, except as specifically authorized.
16. The licensee is authorized to hold radioactive material with a physical half-life of less than or equal to 120 days for decay-in-storage before disposal in ordinary trash provided:
- A. Before disposal as ordinary trash, the waste shall be surveyed at the container surface with the appropriate survey instrument set on its most sensitive scale and with no interposed shielding to determine that its radioactivity cannot be distinguished from background. All radiation labels shall be removed or obliterated, except for radiation labels on materials that are within containers and that will be managed as biomedical waste after they have been released from the licensee.
- B. A record of each such disposal permitted under this license condition shall be retained for 3 years. The record must include the date of disposal, the date on which the byproduct material was placed in storage, the radionuclides disposed, the survey instrument used, the background dose rate, the dose rate measured at the surface of each waste container, and the name of the individual who performed the disposal.

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 6 OF 7 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-00889-01

Docket or Reference No.:
030-02286

Amendment No. 96

17. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
18. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material in the form of unsealed material and foil or plated sources to quantities below the limits specified in 10 CFR 30.72, which require consideration of the need for an emergency plan for responding to a release of licensed material.
19. The licensee shall not use licensed material in field applications where activity is released except as provided otherwise by specific condition of this license.
20. Except for maintaining labeling as required by 10 CFR Part 20, or Part 71, the licensee shall obtain authorization from the U.S. Nuclear Regulatory Commission before making any changes in the sealed source, device, or source-device combination that would alter the description or specifications as indicated in the respective certificate of registration issued either by the U.S. Nuclear Regulatory Commission pursuant to 10 CFR 32.210 or by an Agreement State.
21. Notwithstanding the requirements of License Condition 22, the licensee is authorized to make program changes and changes to procedures specifically identified in the letters dated April 13, 2023 (ML23108A224) and October 13, 2023 (ML23286A259), which were previously approved by the U.S. Nuclear Regulatory Commission and incorporated into the license without prior Commission approval as long as:
 - A. The proposed revision is documented, reviewed, and approved by the licensee's Radiation Safety Committee in accordance with established procedures prior to implementation;
 - B. The revised program is in accordance with regulatory requirements, will not change the license conditions, and will not decrease the effectiveness of the Radiation Safety Program;
 - C. The licensee's staff is trained in the revised procedures prior to implementation; and

Official Use Only - Security-Related Information

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 7 OF 7 PAGES

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-00889-01

Docket or Reference No.:
030-02286

Amendment No. 96

D. The licensee's audit program evaluates the effectiveness of the change and its implementation.

22. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Letter dated April 13, 2023 (ML23108A224)
- B. Letter dated October 4, 2023 (ML23277A286)
- C. Letter dated October 13, 2023 (ML23286A259)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: October 13, 2023

By: **Laura B. Cender** Digitally signed by Laura B. Cender
Date: 2023.10.13 15:58:59 -05'00'

Laura B. Cender
Region 3

**Attachment 1:
Saint Luke's Health System Authorized User List
(SLH, SLN, SLE, SLHC)
NRC License #24-00889-01**

Date of Review: **3/1/2024**

AUTHORIZED USER	AUTHORIZED USE									
	10 CFR 35 Part 100	10 CFR 35 Part 200	10 CFR 35 Part 300	10 CFR 35 Part 400	10 CFR 35 Part 500	10 CFR 35 Part 600	10 CFR 35 Part 1000	Medical Physicist	Human Research	RSO
Sions, Roy										Yes ³
Buckley, Jennifer M.D.	Yes ¹	Yes ¹	Yes ^{1,9}				Yes ^{1,17}			
Davis, Chad M.D.	Yes ¹	Yes ¹	Yes ^{1,9}				Yes ^{1,17}			
Downing, Robert D.O.	Yes ¹	Yes ¹	Yes ^{1,9}							
Holloway, William M.D.	Yes ¹	Yes ¹								
Loskutov, Anatoly M.D.	Yes ¹	Yes ¹	Yes ^{1,9}				Yes ^{1,17}			
Sanchez, Jessica M.D.	Yes ¹	Yes ¹	Yes ^{1,9}							
Saucier, Nathan M.D.	Yes ¹	Yes ¹	Yes ^{1,9}				Yes ^{1,7,17}			
Russell, Gentry, M/D.	Yes ¹	Yes ¹	Yes ^{1,9}							
Shif, Yuri M.D.	Yes ¹	Yes ¹	Yes ^{1,9}							
Wible, Brandt M.D.	Yes ¹	Yes ¹	Yes ^{1,9}				Yes ^{1,7}			
Applebaum, Michael M.D.	Yes ¹	Yes ¹	Yes ^{1,9}							
Childers, Daniel M.D.	Yes ¹	Yes ¹	Yes ^{1,9}							
Culbertson, Scott M.D.	Yes ¹	Yes ¹	Yes ^{1,9}							
Gallet, Bertrand M.D.	Yes ¹	Yes ¹	Yes ^{1,9}							
Gutschow, Susan M.D.	Yes ¹	Yes ¹	Yes ^{1,9}							
Hadley, Wyatt M. D.	Yes ¹	Yes ¹	Yes ^{1,9}							
Kurian, Sarah M.D.	Yes ¹	Yes ¹	Yes ^{1,9}							
Marcus, David M.D.	Yes ¹	Yes ¹	Yes ^{1,9}							
Ruble, Chad M.D.	Yes ¹	Yes ¹	Yes ^{1,9}							
Towsley, Matthew M.D.	Yes ¹	Yes ¹	Yes ^{1,9}							
Varriano, Joseph M.D.	Yes ¹	Yes ¹	Yes ^{1,9}							
Weis, Ronald M.D.	Yes ¹	Yes ¹	Yes ^{1,9}							
Yetter, Ellen M.D.	Yes ¹	Yes ¹	Yes ^{1,9}							

1 Approved by Saint Luke's Hospital RSC

3 Approved by NRC Region III

6 For HDR

6A For HDR contingent on completing Just-In-Time Radiation Safety and Emergency Procedure Training prior to using device
(The individuals listed under 6A have received initial HDR training just not the annual refresher training thus the requirement above)

7 For Y-90 SirSpheres (SLH only)

8 Gadolinium-153 in VANTAGE device

9 Limited to 35.394 I-131 > or < 33mCi only

11 Limited to 35.392 I-131 < 33mCi only

14 For 35.200 (Use of Rb-82 Generator) (Restricted to SLH, SLE, SLN, SLS)

17 For Y-90 TheraSpheres (SLH only)

18 35.396 (SLH only)

**Attachment 1:
Saint Luke's Health System Authorized User List
(SLH, SLN, SLE, SLHC)
NRC License #24-00889-01**

Date of Review: **3/1/2024**

AUTHORIZED USER	AUTHORIZED USE									
	10 CFR 35 Part 100	10 CFR 35 Part 200	10 CFR 35 Part 300	10 CFR 35 Part 400	10 CFR 35 Part 500	10 CFR 35 Part 600	10 CFR 35 Part 1000	Medical Physicist	Human Research	RSO
Bateman, Timothy M.D.	Yes ¹	Yes ^{1,14}			Yes ⁸					
Bybee, Kevin M.D.	Yes ¹	Yes ^{1,14}			Yes ⁸					
McGhie, Arthur M.D.	Yes ¹	Yes ^{1,14}			Yes ⁸					
O'Keefe, James M.D.	Yes ¹	Yes ^{1,14}			Yes ⁸					
Sperry, Brett M.D.	Yes ¹	Yes ^{1,14}			Yes ⁸					
Thompson, Randall M.D.	Yes ¹	Yes ^{1,14}			Yes ⁸					
Rakhra, Sunpreet M.D.			Yes ^{1,18}	Yes ¹		Yes ^{1,6}				
Pham, Yvonne M.D.				Yes ¹		Yes ^{1,6A}				
Herzberg, Susan M.D.				Yes ¹		Yes ^{1,6}				
Bergene, Jennelle								Yes ^{1,6}		
Berhorst, Jason								Yes ^{1,6}		
Ferjani, Samah Ph.D.								Yes ^{1,6}		
Moorehead, Shawn								Yes ^{1,6}		
Sorensen, Scott								Yes ^{1,6}		

1 Approved by Saint Luke's Hospital RSC

3 Approved by NRC Region III

6 For HDR

6A For HDR contingent on completing Just-In-Time Radiation Safety and Emergency Procedure Training prior to using device

(The individuals listed under 6A have received initial HDR training just not the annual refresher training thus the requirement above)

7 For Y-90 SirSpheres (SLH only)

8 Gadolinium-153 in VANTAGE device

9 Limited to 35.394 I-131 > or < 33mCi only

11 Limited to 35.392 I-131 < 33mCi only

14 For 35.200 (Use of Rb-82 Generator) (Restricted to SLH, SLE, SLN, SLS)

17 For Y-90 TheraSpheres (SLH only)

18 35.396 (SLH only)

Martha Pavon

From: Tammy Tomczak
Sent: Wednesday, June 25, 2025 2:18 PM
To: Martha Pavon
Cc: Sandy Pavon
Subject: FW: license 24-01090-03 amendment request
Attachments: NRC_License_Mercy_Joplin 24-01090-03 amendment request signed 062525.pdf

Good afternoon, Martha 😊

Can you please add the attached to ADAMS?

Thank you!!
Tammy

From: Rhoades, Samuel <Samuel.Rhoades@Mercy.Net>
Sent: Wednesday, June 25, 2025 2:07 PM
To: R3-DRSSMail Resource <R3-DRSSMail.Resource@nrc.gov>
Cc: Haywood, Kerri <Kerri.Haywood@Mercy.net>
Subject: [External_Sender] license 24-01090-03 amendment request

Please see attached pdf for our request to add additional AUs.

Samuel Rhoades, PhD, DABR

Medical Physicist & Radiation Safety Officer
Radiation Oncology

Mercy Hospital Joplin

100 Mercy Way | Joplin, MO 64804
Office: 417.556.4463 | Fax: 417.556.2993

Mercy Hospital Pittsburg

1 Mt Carmel Way | Pittsburg, KS 66762
Office: 620.235.7900 | Fax: 620.235.7922

Out of Office:
PTO: June 30-July 8



Find us at:

[Facebook](#) | [LinkedIn](#) | [Instagram](#) | [mercy.net](#) | [Mercy Careers](#)

This electronic mail and any attached documents are intended solely for the named addressee(s) and contain confidential information. If you are not an addressee, or responsible for delivering this email to an addressee, you have received this email in error and are notified that reading, copying, or disclosing this email is prohibited. If you received this email in error, immediately reply to the sender and delete the message completely from your computer system.